Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Tumour microenvironment: informing on minimal residual disease in solid tumours

Nature Reviews Clinical Oncology volume 14, pages 325–326 (2017)Cite this article

Subjects

Patients with resectable solid tumours can harbour minimal residual disease (MRD) after initial treatment, which is a potential source for subsequent metastatic relapse. The interaction between disseminated tumour cells (DTCs) and the new microenvironment in which they reside determines whether DTCs remain dormant or progress into overt metastases. We highlight the promise of liquid biopsies to inform on MRD.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793–802 (2005).

    Article  CAS  Google Scholar 

  2. Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298–1312 (2011).

    Article  CAS  Google Scholar 

  3. Kuske, A. et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci. Rep. 6, 39736 (2016).

    Article  CAS  Google Scholar 

  4. Baxter, L. T. & Jain, R. K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res. 37, 77–104 (1989).

    Article  CAS  Google Scholar 

  5. Goss, P. E. & Chambers, A. F. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10, 871–877 (2010).

    Article  CAS  Google Scholar 

  6. Alix-Panabieres, C. & Pantel, K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479–491 (2016).

    Article  CAS  Google Scholar 

  7. Muller, C. et al. Hematogenous dissemination of glioblastoma multiforme.Sci. Transl Med. 6, 247ra101 (2014).

    Article  Google Scholar 

  8. Mohme, M., Riethdorf, S. & Pantel, K. Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2016).

    Article  Google Scholar 

  9. Cayrefourcq, L. et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 75, 892–901 (2015).

    Article  CAS  Google Scholar 

  10. Ulz, P. et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat. Genet. 48, 1273–1278 (2016).

    Article  CAS  Google Scholar 

  11. Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015).

    Article  CAS  Google Scholar 

  12. Schwarzenbach, H., Nishida, N., Calin, G. A. & Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11, 145–156 (2014).

    Article  CAS  Google Scholar 

  13. Kang, Y. & Pantel, K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23, 573–581 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany

    Klaus Pantel

  2. Department of Cell and Tissue Biopathology of Tumours, Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre, 641 avenue du Doyen Gaston Giraud, 34093, Montpellier Cedex 5, France

    Catherine Alix-Panabières

  3. EA2415 – Help for Personalized Decision: Methodological Aspects, University Institute of Clinical Research (IURC), Montpellier University, 641 avenue du Doyen Gaston Giraud, Montpellier, 34093, Cedex 5, France

    Catherine Alix-Panabières

Authors
  1. Klaus Pantel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Alix-Panabières
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Pantel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pantel, K., Alix-Panabières, C. Tumour microenvironment: informing on minimal residual disease in solid tumours. Nat Rev Clin Oncol 14, 325–326 (2017). https://doi.org/10.1038/nrclinonc.2017.53

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.53

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer